ClosureFast-style radiofrequency ablation of the incompetent saphenous vein — segmental resistive heating, wall contraction, and duplex-confirmed closure
Before any thermal energy is delivered, the entire course of the incompetent saphenous vein must be mapped with duplex ultrasound — combining B-mode imaging of the vein wall and lumen with Doppler flow assessment of reflux. This mapping defines the treatment plan: which segments are truly refluxing, what diameter electrode and catheter size are needed, and where the safest percutaneous access point lies relative to the lowest extent of disease.
The mapping study is performed with the patient standing, using gravity to maximize venous distension and reveal reflux that may be masked in the supine position. The sonographer follows the great saphenous vein (GSV) — or small saphenous vein (SSV) for posterior calf disease — from the saphenofemoral junction (SFJ) or saphenopopliteal junction (SPJ) down to the point where the vein either becomes competent or drops below a treatable diameter (~3 mm).
At each level, two measurements are recorded:
• Reflux duration: augmentation is applied (calf squeeze or Valsalva maneuver) and the duration of retrograde flow measured by pulsed-wave Doppler. Reflux lasting longer than 0.5 seconds in the superficial truncal veins is considered pathologic. • Vein diameter: measured in transverse view at 3–5 cm intervals along the vein's course, since diameter determines both electrode sizing and the expected energy dose needed for durable wall contact.
The skin overlying the vein course is marked at intervals with a surgical marker, creating a real-time roadmap the proceduralist follows during catheter advancement and tumescent infiltration.
Access is obtained at or below the most distal point of measurable reflux, typically at or near the knee for GSV disease. Under continuous ultrasound guidance, a micropuncture needle is advanced into the vein lumen using an in-plane or out-of-plane approach, confirmed by visualizing the needle tip entering the anechoic vein lumen and aspirating venous blood.
A 0.018" guidewire is passed through the needle, followed by sequential dilation and placement of a vascular sheath sized to the RF catheter (typically 7 Fr). Selecting an access point too close to the diseased segment risks leaving untreated reflux distally; selecting one too far proximal unnecessarily shortens the usable catheter working length.
With sheath access secured, the radiofrequency catheter is threaded cephalad under ultrasound guidance until its heating element sits precisely at the treatment starting point — typically 2 cm distal to the saphenofemoral or saphenopopliteal junction, close enough to treat the full refluxing trunk but far enough to avoid thermal injury to the femoral or popliteal vein. Tumescent anesthesia is then infiltrated around the entire length of vein to be treated.
The catheter tip position is the single most important technical step for both efficacy and safety. Positioned too far from the junction, a stump of untreated refluxing vein remains and can be a source of recurrence; positioned too close, thermal energy can propagate into the deep venous system and injure the common femoral or popliteal vein, or promote thrombus extension into the deep system (endovenous heat-induced thrombosis, EHIT).
The operator visualizes the hyperechoic catheter tip in a longitudinal ultrasound view of the junction and adjusts sheath depth until the tip sits at the standard 2 cm safety margin. This position is reconfirmed immediately before the first heating cycle is triggered.
Tumescent anesthesia is infiltrated as a continuous perivenous cuff of fluid along the entire treatment length, injected in small aliquots under direct ultrasound visualization so the fluid is seen surrounding — not entering — the vein. It serves four simultaneous purposes:
1. Anesthesia: dilute lidocaine (typically 0.1%) provides adequate local anesthesia for an awake, tolerable procedure without general anesthesia. 2. Compression: the fluid cuff mechanically compresses the vein around the catheter, improving circumferential contact between the heating electrode and vein wall — critical for uniform energy delivery. 3. Thermal insulation (heat sink): the surrounding fluid volume absorbs and disperses excess heat, protecting the skin, saphenous nerve, and adjacent soft tissue from thermal injury. 4. Hydrodissection: fluid separates the vein from adjacent structures, particularly important near the saphenous nerve, which runs in close proximity to the GSV below the knee and is a recognized source of post-procedure paresthesia if not adequately protected.
A typical tumescent volume is 10–15 mL per centimeter of vein treated — for a 35 cm segment, that is roughly 350–500 mL of dilute anesthetic solution infiltrated as a continuous perivenous cuff before any heat is delivered.
Radiofrequency ablation closes the vein through resistive (Joule) heating: alternating current passed through the vein wall via electrodes in direct contact with the endothelium generates heat from the tissue's own electrical resistance, rather than from light absorption as in endovenous laser ablation (EVLA). The ClosureFast-style catheter automates this into a segmental protocol — a fixed 7 cm heating element treats one segment at a time, then steps backward and repeats, working proximal to distal along the marked vein.
Both RFA and EVLA are endovenous thermal ablation techniques that close incompetent superficial veins, but they deliver energy by fundamentally different physics:
• RFA (resistive/Joule heating): the catheter electrodes are in direct circumferential contact with the vein wall. Alternating current (typically ~460 kHz) passes through the tissue; the wall's own electrical resistance converts current into heat. Because the electrode contacts the wall directly and temperature is measured by an integrated thermocouple with feedback control, the target temperature (~120°C) is reached and held precisely, largely independent of vein diameter or blood content.
• EVLA (optical absorption): a bare or radial-emitting laser fiber emits light (typically 940–1470 nm) that is absorbed by hemoglobin, water, or both, converting to heat within the blood column and vein wall. Because energy delivery depends on chromophore absorption rather than direct wall contact, effective heating is more dependent on blood presence in the lumen and fiber-to-wall distance, historically associated with more heterogeneous heating and vessel wall perforation.
Both mechanisms ultimately achieve the same biological endpoint: collagen denaturation, endothelial destruction, and fibrotic occlusion of the vein — but the closed-loop temperature feedback of RFA produces a more standardized, operator-independent thermal dose.
1. Catheter tip is confirmed at the treatment start point, 2 cm distal to the SFJ/SPJ, under ultrasound. 2. The generator is activated: the 7 cm electrode heats the vein wall to 120°C (or the operator-selected target). 3. The first segment is held at target temperature for 20 seconds — a longer initial cycle to ensure a durable seal immediately adjacent to the junction. 4. The catheter is withdrawn exactly 7 cm (marked on the catheter shaft or automated by the generator), positioning the electrode at the next untreated segment. 5. Each subsequent segment is heated to target temperature and held for 16 seconds. 6. Steps 4–5 repeat sequentially — segment by segment — until the catheter reaches the distal access point and the entire marked vein length has been treated. 7. The generator confirms temperature was maintained within range for each cycle; any segment that fails to reach or hold target temperature is automatically re-treated. 8. The catheter and sheath are removed; manual compression is applied at the access site.
Segmental heating protocol parameters: 7 cm active electrode length · target wall temperature 120°C (adjustable 100–130°C) · first-segment cycle 20 seconds · all subsequent-segment cycles 16 seconds · segments overlap slightly at each withdrawal step to avoid untreated skip zones along the vein.
The visible hallmark of successful radiofrequency ablation is immediate vein wall contraction — a shrinkage of the lumen that can be watched in real time on duplex ultrasound as each segment is heated. This is not a delayed healing response; it begins within seconds of reaching target temperature, as thermal energy denatures the collagen and smooth muscle proteins that give the vein wall its structural integrity.
Collagen's triple-helix structure is stabilized by hydrogen bonds that begin to break down once tissue temperature exceeds approximately 60–65°C, causing the collagen fibers to denature and shrink — this is the same thermal shrinkage phenomenon exploited in other collagen-remodeling procedures. At the RFA target of ~120°C, denaturation is far more complete and rapid, extending through the full thickness of the vein wall (intima, media, and adventitia) rather than a superficial layer.
Simultaneously, smooth muscle proteins in the media layer coagulate, and the endothelial lining is destroyed, eliminating the thromboresistant surface and exposing collagen and tissue factor to circulating blood — triggering local thrombus formation that, combined with the collapsed and fibrosing wall, produces durable luminal occlusion over the following weeks.
On ultrasound, the operator sees the vein lumen narrow and the wall thicken and fold in on itself immediately behind the withdrawing catheter — a real-time confirmation that adequate thermal dose was delivered before moving to the next segment.
Multiple randomized trials and meta-analyses comparing RFA to EVLA have found broadly similar long-term anatomic closure and clinical improvement rates between the two techniques. Where they differ most consistently is in the immediate post-procedure experience:
• Post-procedure pain: RFA is associated with less pain in the first one to two weeks in most comparative studies, attributed to the more controlled, lower-peak-temperature, uniform circumferential heating versus the higher, more variable peak temperatures generated at the laser fiber tip in EVLA. • Bruising (ecchymosis): RFA more often produces less bruising along the treated tract, again consistent with a gentler, feedback-controlled thermal profile compared to the sometimes-uneven energy delivery of bare-fiber lasers. • Return to normal activity: patients treated with RFA frequently report a faster return to normal activity in early comparative series, though differences narrow with modern radial-fiber EVLA devices. • Closure rates: both modalities report anatomic closure in the 90–95% range at one year in contemporary series, with no consistent long-term efficacy advantage for either technique.
The procedure is not complete until closure is confirmed. A follow-up duplex ultrasound — typically performed within the first week — verifies that the treated vein has fully occluded, has no compressibility, and shows no flow. Compression therapy and a structured surveillance schedule then support healing and catch the small minority of cases that recanalize or extend a clot into the deep system.
A structured surveillance schedule is used to confirm closure and detect early complications:
• Within 72 hours to 1 week: duplex scan to confirm full occlusion of the treated segment and to check the saphenofemoral or saphenopopliteal junction for any thrombus extension into the deep venous system (EHIT). EHIT is graded by how far thrombus protrudes into the deep vein, guiding whether anticoagulation is needed. • 6 months: duplex reassessment for durability of closure and to evaluate symptomatic improvement. • 1 year and beyond: many practices repeat duplex annually or as symptoms dictate, since a small proportion of treated veins recanalize — partially or fully reopen — over time, most often at the proximal stump near the junction.
On a fully closed vein, ultrasound shows a thin, non-compressible, echogenic cord in place of the previously patent, compressible, anechoic lumen — with color Doppler confirming the complete absence of flow.
Graduated compression stockings (typically 20–30 mmHg) are applied immediately after the procedure and generally worn for one to two weeks, though regimens vary by practice. Compression serves several roles during healing:
• Reduces perivenous bruising and swelling by limiting extravasation from the treated tract and access site • Improves patient comfort and supports earlier ambulation, which is itself important for reducing deep venous thrombosis risk • Provides symptomatic relief for residual venous hypertension in branch varicosities that were not directly treated but are expected to regress as truncal reflux is eliminated
Patients are encouraged to walk normally starting the same day, while avoiding prolonged standing, heavy lifting, and vigorous exercise for one to two weeks. Most return to routine daily activity within 24–48 hours, one of the recognized advantages of endovenous thermal ablation over traditional surgical vein stripping.
Recanalization surveillance matters because most treatment failures are silent — patients rarely notice a reopened vein until symptoms recur months later. Scheduled duplex follow-up at one week, six months, and one year is what actually catches the small subset of segments (roughly 5–10% by five years) that require repeat treatment.